| 1. |
Rubella and congenital rubella syndrome can be eradicated |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1175,
1999,
Page 2-2
&NA;,
Preview
|
PDF (857KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
| 2. |
News in brief … |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1175,
1999,
Page 3-3
&NA;,
Preview
|
PDF (741KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
| 3. |
Abciximab not cost saving in unstable angina pectoris |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1175,
1999,
Page 4-4
&NA;,
Preview
|
PDF (731KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
| 4. |
Using evidence-based medicine to deliver cost-effective care in CHD |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1175,
1999,
Page 5-7
Carlene Todd,
Preview
|
PDF (2380KB)
|
|
摘要:
There is overwhelming evidence from studies that antihyperlipidaemic drugs are effective in coronary heart disease (CHD) prevention, even though there are many controversies associated with their use. This evidence, although not based on prospective outcomes research under real-life budgetary conditions, has led to the development of treatment guidelines for the prevention of CHD. At the inaugural European conference of the International Society for Pharmacoeconomies and Outcomes Research [Cologne, Germany; December 1998], Dr Karl Lauterbach from the University of Cologne, Germany, outlined a prospective study that aims to help sickness funds decide, under realistic conditions, who should receive statin therapy. Meanwhile, even though evidence-based CHD prevention guidelines are available, the potential for preventive CHD care is not being fully realised by physicians and patients in everyday clinical practice, according to the results of the EUROASPIRE*study.
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
| 5. |
News in brief … |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1175,
1999,
Page 7-7
&NA;,
Preview
|
PDF (784KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
| 6. |
News in brief … |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1175,
1999,
Page 8-8
&NA;,
Preview
|
PDF (730KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
| 7. |
News from the 40th Annual Meeting of the American Society of HematologyMiami Beach, US December 1998 |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1175,
1999,
Page 9-10
&NA;,
Preview
|
PDF (1532KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
| 8. |
HIV recombinant envelope vaccines well tolerated in children |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1175,
1999,
Page 11-11
&NA;,
Preview
|
PDF (773KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
| 9. |
News in brief … |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1175,
1999,
Page 12-12
&NA;,
Preview
|
PDF (755KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
| 10. |
Docetaxelno increase in doxorubicin-related cardiotoxicity |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1175,
1999,
Page 13-14
Robert Carlson,
Preview
|
PDF (1578KB)
|
|
摘要:
Alkylating agents such as doxorubicin have been a standard in chemotherapy for decades, but their use is restricted by dose-limiting cardiotoxicity. This adverse effect can be as significant as congestive heart failure (CHF), but is more commonly represented as a decrease in left ventricular ejection fraction. The severity of these adverse effects generally increases as the cumulative dose of doxorubicin increases. The search for antineoplastic agents that can be combined with doxorubicin to safely increase tumour cytotoxicity is ongoing. While combining the taxane paclitaxel with doxorubicin has boosted response rates, it has also been associated with additional cardiomyopathy. However, the results of studies presented at the 21st Annual San Antonio Breast Cancer Symposium [San Antonio, US; December 1998] indicate that the taxane docetaxel may improve response rates without increasing doxorubicin-related cardiotoxicity.
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
首页
